Treatment of EBV and KHSV infection

Details Treatment of EBV and KHSV infection Treatment of EBV and KHSV infection

2007-05-01

2007-05-01

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S444000, C514S463000, C514S476000, C514S256000

Reexamination Certificate

active

10326444

ABSTRACT:
A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

REFERENCES:
patent: 4247544 (1981-01-01), Bergstrom et al.
patent: 4382925 (1983-05-01), de Clercq et al.
patent: 4424211 (1984-01-01), Jones et al.
patent: 4542210 (1985-09-01), Sakata et al.
patent: 4681933 (1987-07-01), Chu et al.
patent: 4841039 (1989-06-01), Chu et al.
patent: 4957924 (1990-09-01), Beauchamp
patent: 5079235 (1992-01-01), Purifoy et al.
patent: 5356882 (1994-10-01), Walker et al.
patent: 5565438 (1996-10-01), Chu et al.
patent: 5567688 (1996-10-01), Chu et al.
patent: 5587362 (1996-12-01), Chu et al.
patent: 5792773 (1998-08-01), Chu et al.
patent: 6022876 (2000-02-01), Chu et al.
patent: 6177436 (2001-01-01), Spector et al.
patent: 6274589 (2001-08-01), Chu et al.
patent: 2002/0025296 (2002-02-01), Knaus et al.
patent: WO 95/07287 (1995-03-01), None
patent: WO 96/13512 (1996-05-01), None
patent: WO 96/40164 (1996-12-01), None
patent: WO 00/09531 (2000-02-01), None
Lin J-C, et. al. Antiviral Research, 17, 1992, 43-52.
Merck Manual of Diagnostics, 16th Edition, 1992, 2281-2285.
Straus et. al. Epstein-Barr Virus Infections: Biology, Pathogenesis, and Management; Annals of Internal Medicine, 1993, 118, 45-58.
Kumar et. al. Synthesis of 5-[1-hydroxy (or methoxy)-2,2-dihaloethyl]-2′-deoxyuridines with antiviral and cytotoxic activity, Antiviral Research (1994), 24(4), 315-25.
Anisimová, E., et al., (1984) “Effects of n-butyrate and phorbol ester (TPA) on induction of EBV antigens and cell differentiation”Arch. Virol., 81, 223-237.
Ansari, A, et al., (1999) “The U69 gene of human herpesvirus 6 encodes a protein kinase which can confer ganciclovir sensitivty to baculoviruses”J. Virol., 73(4), 3284-3291.
Balzarini, J., et al., (1989) “Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2′-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2′-deoxyuridine”,J. Med. Chem., 32, 1861-1865.
Barba, D., et al. (1994) “Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors”,Proc. Natl. Acad. Sci. USA, 91, 4348-52.
Basnak, I., et al., (1998)Nucleosides and Nucleotides, 17, 29-38.
Beauchamp L.M., et al., (1988) “Effect of acyclic pyrimidines related to 0-[(1,3-dihycroxy-2-propoxy)methyl]guanine on herpesviruses”,J. Med. Chem., 31, 144-149.
Belen'kii, M.S., et al., (1994) “Multiple drug effect analysis with confidence interval”,Antiviral Res., 25, 1-11.
Brand, K., et al., “Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors”,Cancer Gene Therap, 4, 9-16; 1997.
Cannon, J.S., et al., (1999) “Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir”J. Virol., 73(6), 4786-4793.
Caruso, M., et al., (1993) “Regression of established macroscopic liver metastases after in-situ transduction of a suicide gene”Proc. Natl. Acad. Sci. USA, 90, 7024-7028.
Chen, S.-H., et al., (1994) “Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo”Proc Natl Acad Sci USA, 91, 3054-3057.
Cheng, Y.-C., et al., (1983) “Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesvirusesin vitroand its mode of action against herpes simplex virus type 1”,Proc. Natl., Acad. Sci. USA, 80, 2767-2770.
Choi, Y., et al., (2000) “Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes virus”,J. Med. Chem., 43, 2538-2546.
Chou, T.-C., et al., (1984), “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors”,Adv. Enzyme Regul., 22, 27-55.
Culver K.W., et al. (1992) “In vivogene transfer with retroviral vector-producer cells for treatment of experimental brain tumors”,Science, 256, 1550-1552.
Daniel, P., et al., (1989) “Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts”,Clin. Chim. Acta, 181, 255-263.
Datta et al., (1980) “Acyclovir inhibition of Epstein-Barr virus replication”,Proc. Natl., Acad. Sci. USA, 77, 5163-5166.
Datta et al., (1981) “Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid”,Virol., 114, 52-59.
Dyson, M.R., et al., (1991) “The synthesis and antiviral activity of some 4′-thio-2′-deoxy nucleoside analogues”,J. Med. Chem., 34, 2782-2786.
Emery, V.C., et al., (2000) “Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy”,Proc. Natl. Acad. Sci., 97(14), 8039-44.
Gustafson, E.A., et al., (1998) “The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow specificity compared to herpes simplex virus type 1 thymidine kinase”,Antimicrob. Agents Chemother., 42(11), 2923-31.
Gustafson, E.A., et al., (2000) “Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir”J. Virol., 74, 684-692.
Hamel, W., et al., (1996 ) “Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells.”,Cancer Res., 56, 2697-2702.
Herdewijn, P., et al. (1985) “Synthesis and antiviral activity of the carbocyclic analogues (E)-5-(2-halovinyl)-2′-deoxyuridines and (E)-5-(2-halovinyl)-2′-deoxycytidines”,J. Med. Chem. 28, 550-555.
Hoffer, M., (1960) “α-Thymidin”,Chem. Ber., 93, 2777-2781.
Holy, A. (1972) “Nucleic acid components and their analogues. CLIII. Preparation of 2′-deoxy-L-ribonucleosides of the pyrimidine series”,Coll. Czech. Chem. Commun., 37, 4072-4086.
Imamura, K., et al. (1997) “Synthesis andin vitroevaluation of 5-closo- and 5-nido-orthocarbonyluridines as boron carriers”,Bull. Chem. Soc. Jpn., 70, 3103-3110.
Jones, A.S., et al. (1979) “The synthesis of the potent anti-herpes virus agent,E-5-(2-bromovinyl)-2′-deoxyuridine and related compounds”,Tetrahedron Lett., 45, 4415-4418.
Kam, b.L. et al. (1981) “Carbocyclic sugar amines: synthesis and stereochemistry of racemic α- and β-carbocyclic ribofuranosylamine, carbocyclic lyxofuranosylamine, and related compounds”,J. Org. Chem., 46, 3268-3272.
Kim, J.H., et al. (1995) “Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents.”Int. J. Radiat. Oncol. Biol. Phys., 33, 861-868.
Lin, J.-C., et al., (1987) “Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication”,Antimicrob. Agents&Chemotherapy, 31(9), 1431-1433.
Lin, J.-C., et al,. (1988) “Anti-Human Immunodeficiency Virus agent 3′-azido-3′-deoxythymidine inhibits replaction of Epstein-Barr virus”,Antimicrob. Agents&Chemotherapy, 32(2), 265-267.
Lin, J.-C., et al., (1988) “Comparison of two bromovinyl nucleoside analogs, 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil andE-5-(2-bromovinyl)-2′-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication”,Antimicrob. Agents Chemo., 32(7), 1068-1072.
Lin, J.-C., et al., (1984) “Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus”,J. Virol., 50(1),50-55.
Lin, J.C. (1999) “Antiviral therap

Affiliated with

Also associated with

Rating

Treatment of EBV and KHSV infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of EBV and KHSV infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of EBV and KHSV infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3785248